http://www.hardmanandco.com/Research/Alliance_June2005.pdf


Web Site : http://www.alliancepharma.co.uk

http://www.hemscott.com/hstoday/Focus_2005/Alliance%20Pharma_1205_2005.htm

Hardmans late June 2005 update

Fair value at 30p

http://www.hardmanandco.com/Research/Alliance_June2005.pdf

squidd, if you like being a bottom feeder, take a look at OSH, its a high risk, potential high reward one, however, its a recession free industry and one which will continue to grow. The previous CEO messed up a bit and the price got hammered, new CEO was in a month before the last results and I am expecting improved profits, restructuring done and a very positive outlook come reporting time. If you like RAB and their investments, take a look at the shareholders for TAG, expect things to move on that one around June time.

Good news today.

Alliance Pharma PLC
16 March 2005

For immediate release: 16th March 2005



ALLIANCE PHARMA PLC
('Alliance' or 'the Company')


PRE-CLOSE TRADING UPDATE


Alliance Pharma plc, the emerging speciality pharmaceutical company, is pleased
to provide a trading update prior to entering its closed period for the full
year to 28 February 2005.


Profits are anticipated to be within the range of analysts' expectations. Sales
for the year ending 28 February 2005 are expected to be in the region of 11.8
million, up from 10.4 million last year.


Trading performance is showing sales growth of 13%, over the same period in the
previous financial year. Growth on a like-for-like basis was 7%, with a further
6% growth being achieved through acquisitions.


The company made two acquisitions in November 2004: Forceval, a prescription
multivitamin and mineral supplement that is licensed and reimbursed on the NHS
in the UK and sold to various other overseas markets via distributors, and
Periostat, a pharmaceutical treatment for periodontitis, for the UK and all the
other countries in the European Union as well as Switzerland, Israel, South
Africa, Australia and New Zealand.


In the four months since the acquisitions of Forceval and Periostat, the Company
is pleased to announce that sales of both products have been in line with
expectations. Since acquisition, Alliance Pharma has strengthened the
relationships with the international distributors and the order book for
international sales going forward is in line with its expectations. To drive
Forceval's international expansion, the Company is looking forward to announcing
the appointment of a Head of the International Division within the next few
weeks. Similarly, to start to unlock the potential within Periostat, the
appointment of the Head of the Dental Division will be announced shortly


The registration trial programme for Alliance's development drug, misoprostol
for the induction of labour (APL202), which commenced in January, is continuing
according to plan. Approvals are expected soon to permit the trials programme
for Melatonin for sleep disorders (APL 510) to commence.


John Dawson, CEO of Alliance Pharma, commented:


'2004 has been another important year for Alliance. We have continued our
growth and further strengthened our portfolio. Periostat, in particular, has
tremendous growth potential. Good progress has also been made on our
development projects, adding greatly to our mid-term prospects'.


Preliminary results for the 12 month period to 28 February 2005 will be
announced on Thursday 12th May 2005.


- ends -


For further information:



Alliance Pharma plc
John Dawson, CEO
01249 466966


Beattie Financial
John Moriarty
020 7398 3300






This information is provided by RNS
The company news service from the London Stock Exchange

Periostat (mentioned in the trading statement) is one that is going to really boost the P+L account mid term.


Enzyme suppressor as a novel adjunctive therapy for serious gum disease (periodontitis)
Developed by CollaGenex (US)
Sales currently 347k (281k UK)
High growth potential UK sales currently based on 6,000 patients from pool of 3.2m
US sales $45m after 5 yrs
Alliance has agreed contract for EU, Switzerland, Israel, Australia, NZ and S. Africa

As RAB Capital is into APH


Friday 18th March LONDON - Hedge fund manager Rab Capital saw a 65% rise in pre-tax profit and a 75% increase assets under management last year with another surge in January and February of this year.

Pre-tax profit was 17.5m compared with 10.6m last time, a 13-month period to December 2003.

Assets under management by Rab rose to $1.75bn compared to $1.02bn previously, but are now believed to be through the $2bn barrier following a 25% rise in the past two months.

"Performance for the first two months of 2005 has significantly exceeded the same period of 2004 and assets under management have grown strongly since the year end," said the company.

Sales revenue of 36.2m came in 56% higher than 2003. Management fees went up from 6.6m in 2003 to 10.1m in 2004.

The dividend for the year doubles to 0.50p from 0.25p in 2003.

PpP: Having looked at APH, I feel no urge to climb aboard at present. It has a bland website, miniscule director buys, low traded volumes and no sign yet of recovery on the charts. TED looks much more promising on all these counts and have recently bought them. However, with the heavyweight institutional support for APH that you point out, they are now on my watch list.
OSH came up on my radar with modest director buys, but so far they seem to be stuck in a downtrend; and I can't find a proper website for them, only something about dentistry, so will contine to watch.
sd.

squidd : At present it appears nothing exciting at APH short term, I shall be looking for any more institutional support that comes in short term, and then the news on results. APH looks attractive presently in the mid term, but as we all know, anything can happen, I would not expect any short term downside or bad news - so even holding in the short term "can" only give upside on good news.

OSH web site is www.oasis-healthcare.com. This is a recovery play. High turnover and high debt (debt is due to building the group) - the debt is "not" a worry IMO owing to the business plan. If the results are good, this will rebound strongly. The new man in charge, Stephen Lambert, in for a year now, should have turned it around - so potential large bounce on the results. OSH are trying to do the same with dentistry as Boots and the like did with pharmacy - take a fragmented market and turn it into a large group. Its a growing market and recession proof. Just need to wait and see if Lambert has made the changes needed, after the last man messed up a bit. IMO, turn around will be stated soon.

PpP: Wakened by the sweet sound of much needed rain. Thanks for updated info on APH and OSH; both high on my watch list.
Have you looked at my earlier pharma recovery stocks - TED and post-crash ELA.
sQd.

Alliance Pharma PLC
30 March 2005

For immediate release: 30 March 2005





ALLIANCE PHARMA PLC

('Alliance' or 'the Company')


SHAREHOLDINGS IN COMPANY



Fidelity acquire an additional 3,700,000 ordinary shares





On 30th March 2005 the Company was notified by Fidelity Investments, ('FMR Corp
'), that it had increased its shareholding by 3,700,000 shares. The notifiable
interest is with FMR Corp and Fidelity International Limited (FIL) which also
comprises the notifiable interest of Mr Edward C Johnson 3d, a principal
shareholder of FMR Corp and Fidelity International Limited. The shares held
currently are as follows:


Shares Held Management Company Nominee/Registered Name
240,500 FIL Brown Brothers Harriman Ltd LUX
9,959,500 FMRCO Mellon Bank
TOTAL 10,200,000



The total percentage shareholding of FMR Corp and Fidelity International Limited
is now 9.43%

Prelims est 12th May.

We have a buyer it seems, looking at trade values and timings.

16:38:44 13-Apr-2005 13.00 50,000 6,500.00 Single protected transaction
16:38:44 14-Apr-2005 13.00 50,000 6,500.00 Single protected transaction

Same time to the second.

Another 50K today at 16:38 and 44 seconds ?

13M Cross Trade today (9% of all shares)

Alliance Pharma PLC
09 May 2005


For immediate release 9 May 2005

ALLIANCE PHARMA PLC
('Alliance Pharma' or 'the Company')

Announces Co-Promotion Agreement with OralDent Ltd

Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
is pleased to announce a co-promotion agreement with OralDent Ltd ('OralDent'),
a privately owned dental products company, for the UK marketing and distribution of Periostat(R), a prescription medicine for the treatment of the severe gum disease periodontitis.

Periostat is a major growth opportunity for Alliance Pharma and this agreement
with OralDent marks the first step in the roll-out of the product across the
territories for which the Company holds marketing rights. Alliance Pharma
acquired the rights in November 2004 from CollaGenex International Ltd, part of
CollaGenex Pharmaceuticals Inc (Nasdaq: CGPI), for the territories of the
enlarged European Union, Switzerland, Israel, Australia, New Zealand and South
Africa.

The international roll-out of the product will be led by a senior international
manager, who was recently appointed to head the Company's newly formed
International Division.

OralDent focuses on promoting products to private and NHS dentists in the UK via a field sales force, a tele-sales operation and an internet portal. Alliance Pharma will contribute resources to enable OralDent to increase the size of its sales force to maximise the sales of Periostat. Alliance Pharma will recognise the Periostat sales and OralDent will receive sales-based royalties on a sliding scale between 5%per cent and 15% per cent.

Periostat is the first and only approved oral pharmaceutical product for the
adjunctive treatment of adult periodontal disease (periodontitis) by the
suppression of those enzymes that destroy periodontal support tissues. Periostat is included in the Secretary of State for Health's list for dental prescribing and is listed on the UK's Dental Practitioners' Formulary. Periodontitis is estimated to affect 11 per cent of the adult population in the UK.

Commenting, John Dawson, Alliance Pharma's Chief Executive, said: 'Periostat is
a major growth opportunity for the Company and this UK co-promotion agreement is an important first step in maximising the potential of the product. OralDent has a particularly strong franchise in the UK dental market and we look forward to a successful collaboration with them.'

For further information:

Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director

www.alliancepharma.co.uk

And some strong buying yesterday.

PpP: I see our favourite pharma's continue to storm uphill and thanks to a takeover rumour today, ELA takes the lead. Nice to see some splashes of blue inside, with the bluebells outside.
sd.

Read this today squidd

One top market analyst turns bullish on the undervalued shares of major pharmaceutical companies.

NEW YORK May 10th 2005 - Among the important market analysts I follow, Steve Leuthold is one of the best. His Leuthold Group does extensive historical analysis of the stock and bond markets chiefly for institutional investors.
The firm maintains a managed model stock portfolio that is conservative and value-oriented. Moreover, the portfolio mix changes only slightly from month to month. So when Leuthold makes a major move, it's worth taking seriously.
As of May, the Leuthold Group has added the major pharmaceuticals group to its model portfolio. The big drug stocks were last rated Attractive by the firm in June 2003.
The firm's analysts have been intrigued by the beatings that big pharmaceutical companies took during the past several months, says Leuthold, and were waiting for this down and out group to reach attractive valuation levels again.
The big drug stocks currently trade at price/earnings ratios of 14 to 21, based on estimated 2005 earnings, and yield from 2 percent to 4.4 percent. By comparison, the average blue chip now trades at a 17 P/E, and the S&P 500 yields only 1.9 percent.
This portfolio adjustment is just the latest increase in the Leuthold Group's broader commitment to health care. The firm's core portfolio now has a 26 percent allocation to health care, while that sector accounts for less than 14 percent of the S&P 500's market cap.

More good news squidd

Alliance Pharma PLC
11 May 2005


For Immediate Release 11 May 2005




Alliance Pharma Plc

Notification of Major Interests in Shares

Nigel Wray acquires additional shares in Alliance Pharma



On 5 May 2005, the company was notified by Nigel Wray that he has purchased an
additional 700,000 shares in the company bringing his total holdings in Alliance
Pharma to 6,355,407 ordinary shares or 4.31% of the issued share capital.


-ENDS-

PpP: Thanks for this. Obviously, Nigel doesn't share my concerns about the big picture and this is highly encouraging. I'm clearing out some dogs from my portfolio at present and will look again in a few days.
sd.

Squidd here we go.


Alliance Pharma PLC
12 May 2005
For Immediate Release 12 May 2005

ALLIANCE PHARMA PLC

('Alliance Pharma' or 'the Company')

Preliminary Results for the year ended 28 February 2005



Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
is pleased to announce its preliminary results for the year ended 28 February
2005. These are the Company's first full year results as a listed company,
following the Company's admission to AIM in December 2003.

Financial Highlights


Turnover increased 13% to 11.8 million (2004: 10.4m) - the full year
impact of two product acquisitions in November 2004, Periostat(R) and
Forceval(R), would show an annualised turnover of 15m

Gross margin improved to 52.4% (2004: 48.4%)

Adjusted EBAT (earnings before exceptional items, amortisation and
tax) of 0.645 million (2004: 1.21m) - the decrease largely reflecting the
investment in infrastructure and the marketing expenditure associated with
current and pipeline products

Profit before tax of 0.418 million (2004: loss of 2.15m)

Operating cashflow remains strong at 1.59 million (2004: 2.11m)

Adjusted earnings per share 0.52p (2004: 1.18p)

Basic earnings per share 0.34p (2004: loss per share of 2.44p)


Operational Highlights

Continued strong sales growth of Symmetrel(R)and Nu-Seals(R)

Acquisition of Periostat and Forceval in November 2004

Regulatory approval anticipated imminently to begin clinical trials of
Posidorm(TM), melatonin in sleep disorders

Start of Phase III clinical trials in January 2005 of APL 202
misoprostol for the induction of labour

Launch of International division to drive overseas sales through
out-licensing and distributors

Co-promotion agreement signed with OralDent Ltd for the UK marketing
and distribution of Periostat(R), a prescription medicine for the treatment
of the severe gum disease periodontitis


Commenting on the results, John Dawson, Alliance Pharma's Chief Executive, said:
'These results underline the robustness of Alliance Pharma's business model, in
which the cashflow from our marketed products supports the development of our
clinical pipeline. We will shortly commence the trial programme leading to
registration for our product Posidorm(TM) for sleep disorders, which seeks to
address a market that is currently at 0.5bn but which is expected to treble in
the next decade.'

For further information:

Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director

www.alliancepharma.co.uk

squidd another potential one to add to the recovery pipeline is Kuju (KUJ) who have done their changes some time ago and with some excellent recent contract news which should grow with E3 not far away. They also I hope should be returning to profits in the results due not so far in the future with their new set up and working method allowing profitable growth and a confident outlook statement.

Been noticing that some shorters are working on some sites to slag off companies like OSH APH VLK this is a good sign as they are trying it on with the general weakness hoping to bring the price down so they can then go long over the summer and autumn. Hitting the shares that are already priced down on previous old bad news is easy and often they post no facts or just old news but I think they might fail as people can see the return well underway to better times ahead.

ELA still looking good.

Have you looked at UNG ? its been hit and things are very positive for the future and the price to book value is well under 1

squidd there is more good news here too as well as UNG;

Alliance Pharma PLC
16 May 2005
For Immediate Release 16 May 2005



ALLIANCE PHARMA PLC

('Alliance Pharma' or 'the Company')

Director's Share Dealing

Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
is pleased to announce that Michael Gatenby, Chairman of Alliance Pharma plc,
purchased 50,000 shares at 14.45p, bringing his total in the company to 130,000
shares which represents 0.088% of the total issued share capital.

For further information:

Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director

www.alliancepharma.co.uk